Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655139 | 0.88 | CHEK1 (0.75) | CHEK1CDK7 | |
| SCHEMBL13655147 | 0.88 | CHEK1 (0.75) | CHEK1CDK7 | |
| SCHEMBL4159550 | 0.87 | CHEK1 (1.00) | CHEK1CDK7 | |
| SCHEMBL27708364 | 0.85 | CHEK1 (0.76) | CHEK1CDK7 | |
| SCHEMBL5058880 | 0.84 | CHEK1 (1.00) | CHEK1CDK7 | |
| SCHEMBL5058886 | 0.84 | CHEK1 (1.00) | CHEK1CDK7 | |
| SCHEMBL5061280 | 0.84 | CHEK1 (1.00) | CHEK1CDK7 | |
| SCHEMBL4164628 | 0.84 | CHEK1 (1.00) | CHEK1CDK7 | |
| SCHEMBL5058860 | 0.84 | CHEK1 (1.00) | CHEK1CDK7 | |
| SCHEMBL4158960 | 0.84 | CHEK1 (1.00) | CHEK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MAPT, PSEN2, PSEN1 | CHEK1 1733/4885CDK7 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.